Impact BioMedical Inc (IBO) - Long-Term Debt to Capital

The quotes provided below help assess the risks of the Document Security Systems venture division, where a lack of stable sales renders cash flow unpredictable. Meanwhile, the company is developing a diversified incubator with a focus on intellectual property, while revenue relies on royalties from biomedical patents and nutraceuticals. The current metric stands at 0.00, which is critical for analyzing early-stage assets.

For Impact BioMedical Inc (IBO), which generates no revenue due to the early stages of drug development, analyzing the long-term debt-to-equity ratio is critical. This metric compares liabilities with a maturity of over one year against the company's own equity. By examining this long-term financial stability indicator, an investor assesses the proportion of debt financing within the asset structure. An increasing ratio coupled with a cash deficit signals a risk of insolvency, which determines the overall viability of the business.